《Amicus Therapeutics, Inc. (FOLD) 2024年CSR报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Amicus Therapeutics, Inc. (FOLD) 2024年CSR报告「NASDAQ」.pdf（50页珍藏版）》请在三个皮匠报告上搜索。
1、2024Environmental,Social,and Governance ReportIN THE FIGHT TO REMAIN AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASESCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report1Table of ContentsOverview2Message from the President&CEO3About Amicus4
2、Amicus Aspirations&Achievements5ESG Program6Our ESG Initiatives&UN Sustainable Development GoalsEnvironmental Stewardship8Environmental Stewardship&Corporate Responsibility9Sustainability within Supply10Strengthening our Commitment to ESG through our PartnershipsPatients12Patient Advocacy13Patient A
3、dvocacy and Engagement14Pricing Promise and Commitment to Patients15Access&Affordability17Safety of Clinical Trials18Product QualityEmployees20Our Responsible Business21Talent Pipeline Development Strategy22Leadership Development and Learning Programs23Career Development Plans24Employee Recruitment,
4、Engagement,and Retention27Employee Wellness28Human Capital29Diversity,Equity,and Inclusion30Employee Resource Groups31Corporate Social Responsibility32Employee Involvement in the CommunityGovernance34Ethical Business Practices and Marketing36Compliance Program37ESG Governance38Board of Directors39En
5、terprise Risk Management40Data Security and Privacy41CybersecuityCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report2I am pleased to share with you our annual Environmental,Social,and Governance(ESG)report and the initiatives we see as critical to o
6、ur long-term success and our impact as a global biotechnology company.Everyday Amicus is driven by a shared sense of purpose and commitment to people around the world living with a rare disease.Our work is founded in the belief that every person living with a rare disease deserves access to effectiv
7、e treatments.We also recognize that our responsibility extends beyond just the world of biotechnology and development of new therapies.To that end,we embrace our responsibility as stewards of the environment,social progress,and governance practices that are aligned with the values of our stakeholder
8、s.Our accomplishments in 2023 represent the dedication Amicus brings to the rare disease community as we continued our mission of transforming the lives of people living with rare diseases.Our achievements last year were highlighted by:Increasing access to Galafold with over 2,400 people living with
9、 Fabry disease around the world Receiving regulatory approvals of our second commercial therapy,Pombiliti+Opfolda,in the United States,European Union,and the United Kingdom Delivering on our commitment to achieve non-GAAP profitability in the fourth quarter of the year Supporting a mission-focused c
10、ulture where employees can contribute to winning teams,feel included,supported,and heard.Furthering our culture of strong business ethics and sound corporate governance philosophies Continuing to integrate sustainability best practices in our operations while delivering strong business growth Suppor
11、ting our communities through global charitable giving These achievements were accomplished through the hard work and commitment of our almost 500 employees.Our teams have worked to fulfill our mission and bring our treatments to as many people as possible.As we reflect on the past years accomplishme
12、nts and set our sights on the year ahead,I extend my heartfelt gratitude to our employees,partners,and stakeholders for their support and dedication.We believe that through our shared sense of purpose,as well as,our ESG initiatives,we can create a better future for people living with rare diseases,o
13、ur communities,and the world.Together,we will continue to drive positive change,create shared value,and build a more sustainable future.Sincerely,Bradley L.CampbellPresident and Chief Executive OfficerMessage from our President&CEOAmicus Therapeutics2024 ESG Report2Company OverviewEnvironmental Stew
14、ardshipPatientsEmployeesGovernance2 2Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report3About UsWe are a global,patient-dedicated biotechnology company focused on developing and delivering high-quality medicines for people living with rare diseases
15、.Amicus,the Latin word for friend,signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way.This spirit of empathy,compassion,and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge tech
16、nologies.Definition:/:mks(noun)Latin FriendAmicus Therapeutics2024 ESG Report3Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report4Environmental Stewardship Minimize our carbon footp
17、rint Engage and inform employees around good sustainability practices Increase usage of energy efficient lighting,appliances,and materials in our corporate offices Developing sustainability objectives with our manufacturing and supply partners to reduce GHG emissions Working towards quantifying our
18、CO2 emissions produced during the supply chain Continue to have excellent oversight of climate related risks by identifying and implementing metrics to support oversightSocial Remain at the forefront of therapies for rare and orphan diseases Deliver the highest quality therapies for people living wi
19、th these diseases Invest in a pipeline of next-generation therapies for those living with rare diseases Continue to support the disease communities and their families Encourage access to medicines through responsible pricing,disease awareness,and supportive services Provide a corporate culture that
20、drives performance and ultimately attracts,energizes,and retains critical talentGovernance Maintain and foster our culture of strong business ethics and integrity,and ensure open lines of communication to encourage employee compliance reporting Continue partnering with all employees and stakeholders
21、 to ensure transparency and proper training on policies,procedures,and best practices Robust risk oversight by senior leadership and the Board of DirectorsAmicus Aspirations&Achievements2023 Achievement Highlights Two approved therapies for the treatment of rare diseases:Galafold for Fabry disease a
22、nd Pombiliti+Opfolda for late-onset Pompe disease 2,600+individuals treated through commercial,clinical,and expanded access programs 40+countries with regulatory approval Received three prestigious awards for Pombiliti+Opfolda for our innovation and contributions towards improving the quality of hea
23、lthcare and patient outcomes:WORLDSymposium 2024 New Treatment Award BioNJ 2023 Innovator Award Life Sciences PA 2023 Patient Impact AwardCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report5ESG ProgramOur dedication to patients goes hand in hand wit
24、h our commitment to our environmental,social,and governance(ESG)program.Building strong ESG practices and oversight into our scientific and business activities creates a culture of integrity at every level of the organization,while safely and effectively delivering on our founding beliefs be at the
25、forefront of therapies for rare and orphan diseases,create long-term value for our stakeholders,and foster teamwork and respect for individual contributions.Our foundational ESG initiatives are consistent with those identified by the Sustainability Accounting Standards Board(SASB)for the biotechnolo
26、gy and pharmaceuticals sector,and serve as a broad guide for our report content.We have also aligned our personal ESG practices and aspirations with several of the Sustainable Development Goals adopted by the United Nations in 2015.These goals provide a shared blueprint and call to action for all co
27、untries to foster initiatives that promote peace,prosperity,and a sustainable future for people and the planet.Additionally,in an effort to increase our awareness of our environmental impact,we have engaged with CDP,the gold standard in environmental reporting,for greater transparency into our envir
28、onmental disclosures,as well as those within our supply and value chains.The development and delivery of critical therapies for patients,clinical and regulatory compliance,employee engagement,and responsibility to our investors are underscored by our commitment to sustainable organizational developm
29、ent and growth.It is our belief that a sound governance structure,coupled with a socially and environmentally responsible mindset,provides the foundation for collective decision making and accountability across all facets of Amicus.Evolving our ESG program and its initiatives is a key goal for Amicu
30、s,and we look forward to reporting additional data and metrics relative to our ongoing progress on an annual basis.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report6Our ESG Initiatives&UN Sustainable Development GoalsEnvironmental StewardshipRespo
31、nsible Consumption and ProductionAmicus strives to integrate environmentally-conscious business practices and sustainability efforts into the day-to-day and long-term business to promote an environmentally-conscious corporate culture.Human CapitalGood Health and Well-BeingAmicus is committed to ensu
32、ring the health and well-being of our global employees and people living with devastating rare diseases who can benefit from our therapies through global commercial,clinical and expanded access programs.Quality EducationAmicus adopts career development initiatives and provides our employees the tool
33、s and resources to grow personally and professionally to ensure we can meaningfully engage with the global rare disease community.Gender EqualityAmicus is dedicated to fostering an inclusive culture and works diligently to ensure equal participation for all in critical decision making,and the same o
34、pportunities for upward mobility.GovernancePeace,Justice,and Strong InstitutionsAmicus is founded on core principles of integrity,accountability,and transparency,and governs with a set of business ethics that promote a culture of compliance that is supportive of equal opportunity and representation.
35、Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report7Environmental StewardshipOur eco-friendly decision-making has identified economic efficiencies while continuing to bolster our standing as a good corporate citizen.In this SectionCommitment and Obj
36、ectives Sustainability within Supply Strengthening our Commitment to ESG through our PartnershipsAmicus Therapeutics2024 ESG Report7Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceUN Sustainable Development GoalsCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernance
37、Amicus Therapeutics2024 ESG Report8Environmental Stewardship&Corporate ResponsibilityWe are committed to producing transformative medicines for patients while practicing environmental responsibility and adhering to sustainability best practices in our operations.Reducing our FootprintAs a biotechnol
38、ogy company,our environmental footprint is relatively small in comparison to many other industries,yet we strive to minimize our footprint as much as possible.At Amicus,we recognize the severity of environmental impact and the need to continuously identify and assess areas of risks.As a result,we ar
39、e working towards implementing robust sustainability objectives into our operations and with our manufacturing and supply partners to achieve a reduction in greenhouse gas(GHG)emissions.2023 Sustainability Program Objectives Achieved Continued to capture risk and opportunities in our partners sustai
40、nability programs Implemented contractual obligations with suppliers to maintain good sustainability practices through their own ESG programs and review those programs as a standing agenda item in formal business reviews Engaged employees around good sustainability practices through the GREEN employ
41、ee resource group(ERG)to further educate on how Amicus and individuals can reduce our carbon footprint Greater efforts towards reducing our carbon footprint through a reduction in our facilities,increased hybrid working,and occupying office space that is commutable by walking,mass transit,or shared
42、rides Continued efforts towards gaining a better understanding of both Amicus and our partners GHG emissions and developing reduction targets to achieve our aspirational goal of carbon neutrality0%Amicus does not own any manufacturing facilities resulting in 0%Scope 1 and 2 GHG emissionsEngaging Emp
43、loyees in SustainabilityAt Amicus,we recognize the importance of our employees passion in fulfilling our sustainability commitments.In 2024,we plan to offer new opportunities for our employees to engage with sustainability both inside and outside of work.We value our employees input and will continu
44、e to listen to their suggestions and share updates on our sustainability efforts via company events and environment-related volunteering.In April 2023,Amicus celebrated Earth Day globally in our Princeton,Philadelphia(USA),and Marlow(UK)offices.We handed out seed packets and hosted a“Plant a Seed fo
45、r Good”event for employees to promote native wildlife and learn about the GREEN ERGs volunteering and giving opportunities.Throughout 2023 Amicus held additional events for employees to learn more about community-led initiatives on sustainability such as,“Transition Town Marlow,”“Emergency Relief As
46、sociation,”and“Operation Crop Drop.”Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report9Sustainability within SupplyAmicus Supply Partners Committed to Improving Green CredentialsAt Amicus,sustainability means creating lasting social,environmental,a
47、nd economic value by addressing the needs of the companys wide-ranging stakeholder base,including our manufacturing and distribution partners.Our mission is to drive sustainability with our partners,by incorporating environmental and sustainability principles into our commercial relationships.In ord
48、er to do this,we want to ensure that we are aligned in our approach and establish the right priorities to help drive change.Environmental Oversight and Risk Assessment of Our Supply PartnersOur understanding of our suppliers progress in implementing their own ESG programs continues to grow.We issued
49、 our annual survey to our suppliers and in all cases,it is evident that their programs continue to mature.We have now joined with CDP(a global platform for disclosing environmental information),to engage directly with our partners and consolidate environmental information across our entire supply ch
50、ain.Working closely with our suppliers,we intend to utilize this information to bolster our own sustainability program and create a basis for direct action to improve our sustainability.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report10Strengthen
51、ing our Commitment to ESG through our PartnershipsAmicus Priorities for our Partners in 2023:CompleteEnd to End CO2Supply Chain assessments Collate CDP 2023 supplier performance ratings Develop insights and align objectives within supplier governance meetings Engage with suppliers through CDP for th
52、e disclosure of 2024 data Complete Amicus 2024 CDP submission by the published deadlineWe routinely assess and monitor the progress of all incumbent suppliers regarding:Company and site information Environmental Sustainability Programs:Policy Communication Reporting Human Rights and Safety:Ethical p
53、ractices Legal compliance CO2 and Natural Resources:Programs to reduce greenhousegas emissions Renewable energy Water conservation Environmental Monitoring:Greenhouse gas emissions Waste from manufacturing processes Enhanced Product Stewardship:Product lifecycle management Recycling Supplier diversi
54、tyIn 2023,we continued to make great progress towards understanding our suppliers ESG objectives:Instigated an annual reviewof ESG performance acrossan extended list of directsuppliers Conducted deep-dive reviewsof sustainability programs withkey partners Joined the CDP SupplyChain Program Continued
55、 to incorporate ESGclauses within our suppliercontracts New supplier introductionnow requires satisfactorycompletion of our ESGquestionnaire and agreementto the termsCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report11UN Sustainable Development Goa
56、lsPatientsEvery biotech company is focused on patients,but at Amicus we do it differently;we consider the needs of patients first in everything we do.In this SectionPatient Advocacy Pricing Promise Access&Affordability Safety of Clinical Trials and Product QualityAmicus Therapeutics2024 ESG Report11
57、Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report12Patient AdvocacyAt Amicus,dedication to patients has always been our primary focus and motivation.We are committed to being the
58、bridge between individuals and families affected by rare diseases,and the resources that offer education,support,and empowerment as they access essential services throughout their disease experience.Amicus Patient&Professional Advocacy(P&PA)collaborates with patient organizations,individual patients
59、,their caregivers,and healthcare practitioners to ensure we are doing all that we can to help support the rare disease community.We pioneered patient centricity in biotech not only from a leadership perspective but also by always informing our technologies,programs,and services with what weve been h
60、onored to learn from our patient partners.Patient Advisory BoardsOur long-standing Patient Advisory Boards(PAB)give those living with these rare diseases an opportunity to share their insights and experiences.The purpose of a PAB is to bring together a group of informed individuals that represent a
61、diversity of disease experience,age,geography,and perspective and have a connection to the broader patient community.As the true experts in their disease,they help us understand unmet medical needs,what is most meaningful to them and their families,and the outcomes that can make clinical and quality
62、-of-life differences.PABs will continue to play an important role at Amicus.The Community of UsWe empower patient communities to ensure that their perspective is expressed and listened to.We are committed to working with the patient and professional communities to meet the unmet needs of the rare di
63、sease community and support full access to education,diagnosis,medication,and service provision for rare diseases.We are tenacious allies with the rare disease community and take pride in the trusted relationships built with patient advocacy organizations,their leaders,and members.Company OverviewEn
64、vironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report13Patient Advocacy and EngagementEducational Resources for Patients and their FamiliesBy collaborating with our PAB members,Patient Advocacy Organization(PAO)leaders,and healthcare providers,knowledge gaps and prefer
65、ences are identified.We then develop and offer resources to educate individuals on disease state and products and encourage patients to become their own best advocates.The aim is to better equip them with the right information to have better and more constructive conversations with their HCPs that s
66、upport shared decision making for their care.Those who know more and understand the impact of the disease they are living with are in a better position to manage it.Through the Community of Us,Fabry and Pompe disease educational websites were created to help patients understand their disease:Pompe D
67、isease Resources for Patients and Families Fabry Disease Resources for Patients and Families Visual Learning Guide for Fabry Visual Learning Guide for PompeAdditional resources can be found on our Amicus corporate website at https:/ to Generate Awareness and Increase AccessWith the rare disease comm
68、unity:Amicus Community Champions Program:By sharing their own experiences,people affected by Fabry disease or Pompe disease use the power of storytelling to help generate disease awareness,motivate others in their communities,and help patients work more effectively with their healthcare teams Advoca
69、ting for newborn screening initiatives in the U.S.:Amicus provides charitable support for newborn screening summits and advocacy efforts Upon approval and launch of PomOp:Patient support programs were put in place to assist patient access to this new therapyWith Policymakers,Amicus continues to driv
70、e active discussions of public policy issues that can advance access and equity in the rare disease space and a policy climate that stimulates and supports innovation.We do this in concert with national and international rare disease and industry associations,and by helping patient communities incre
71、ase their understanding and ability to advocate for policies to improve access.Our Good Stuff Created by a mom Margo,living with epilepsy and her daughter Naomi,living with Fabry disease,Our Good Stuff is designed to help people stay optimistic in the face of rare disease.With the creation of Our Go
72、od Stuff we want to help them harness their experience and share with others that even the simplest moments can help lead to inspiring outcomes.Whenever something positive happens big or small write it down and collect it in a jar.At the end of every year,or whenever you need to,pull out your jar an
73、d read all your thoughts of positivity to reflect and celebrate all the good in the year gone be.Youll see that even the challenging days had good in them.Being persistently positive in the face of rare diseaseCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics202
74、4 ESG Report14Pricing Promise and Commitment to PatientsAt Amicus,we believe the life sciences industry and the people we serve need bold leaders and responsible innovators.We recognize that our commercial products can only be successful if the patients who may benefit from them have access to them.
75、Our Amicus Pricing PROMISE(Price Our Medicines responsibly In order to Serve patients and Enable innovation)reflects our corporate belief that“our medicines must be fairly priced and broadly accessible”.This includes our promise to price our therapies at no additional cost to payors compared to simi
76、lar competitor products in each geography.We work collaboratively with payors on access,and importantly,do not raise the price for any Amicus medicine annually more than the Consumer Price Index(CPI).This is something that weve carried with us through the Galafold launch,which has proven to be a sou
77、nd business strategy,and weve now applied to the global launch of Pombiliti+Opfolda.Effectively,keeping price increases at CPI encourages access to the drug,which we believe means more patients can gain access to our therapies without undue burden on the individuals or the healthcare system.SASB:HC-
78、BP-240a.1Patient Support ProgramsWe have made great strides in bringing medicines to the rare disease community which has so many unmet needs.We will continue to strive so that in the future more people living with rare diseases will have treatment options.Amicus has developed patient support progra
79、ms in both the United States(U.S.)and internationally to help individuals gain access to our medicines,even when there are barriers to access or financial hardships.Amicus Assist is a patient support program for patients who have been prescribed an Amicus medication in the U.S.Amicus Assist helps pa
80、tients access their medication and can identify possible sources of financial assistance.For more information on Amicus Assist in the U.S.,visit our website at .Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report15Access&AffordabilitySince the compa
81、nys earliest days,extraordinary dedication to people affected by rare and orphan diseases has been a hallmark of Amicus.Rare genetic diseases,by nature,are less common and often under-or misdiagnosed.Thus the global population of individuals living with rare diseases is much smaller than those of mo
82、re prevalent diseases.Despite having a smaller global patient population,Amicus is committed to delivering our medicines to thousands of people around the globe,both through commercial and expanded access.Our Commitment to Growing our Commercial ReachWe have proudly developed and delivered two novel
83、 therapies that we believe have the potential to make a positive impact on the rare disease community.With the development of our medicines,comes the promise that these medicines will be broadly accessible.We are committed to expanding the global commercial reach of both our products,and our teams h
84、ave been successful in working with global regulators and pricing authorities to gain marketing authorizations for the commercial access of Galafold,and now Pombiliti+Opfolda,in many countries throughout the world.Expanded Access Program(EAP)Our ultimate goal is to provide access through marketing a
85、uthorization;this approval route enables access to as many people as possible.However,before our product candidates might become available through these means,we are committed to providing access where they are not yet commercially available through carefully designed and considered expanded access
86、pathways.Our cross-functional management committee oversees all activities related to EAP to ensure we maintain our patient focus and do all that we can to provide access to those who have the highest need.2,600 patients on our therapies through commercial,clinical,and expanded access programs.Pombi
87、liti+Opfolda for Late-Onset Pompe DiseaseIn 2023,Amicus announced the approval and commercial launch of Pombiliti+Opfolda for the treatment of adults living with Late-onset Pompe disease in the U.S.,EU,and U.K.,the three largest Pompe markets.Throughout 2024,we will continue to focus on increasing p
88、atient access by expanding into additional major markets with multiple ongoing or planned regulatory submissions and pricing and reimbursement interactions expected this year.Expanded Access through 2024:Delivering our therapies to patients in need.32/24patients countriesGalafold for Fabry Disease40
89、+Countries with regulatory approvals Commercial Expanded Access Commercial&Expanded AccessPombiliti+Opfolda3 Now approved in 3 key marketsCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report16Health Equity:Diversity of Clinical TrialsIncorporating th
90、e patient perspective into every step of the drug development process means ensuring accurate representation of the various racial ethnicities,genders,and cultural backgrounds that make up our society.Amicus firmly believes in advancing our efforts to ensure greater diversity throughout our clinical
91、 trials so that all individuals can benefit from our scientific advancements.Consistent with Amicus extraordinary patient dedication,we strive to attain representation and diversity in our clinical trials.Rare diseases are,by definition,conditions affecting very small patient populations,but we are
92、proud of the reach of our clinical programs and the diversity of research participants.Throughout 2023,Amicus has collaborated with internal and external stakeholders on strengthening health equity in our own clinical trials and the rare disease space.We are committed to being an active member in th
93、e discussion of diversity in clinical research and advocating for greater diversity across our own clinical trials and those of our industry peers.Advocating for Diversity in Clinical Trials in 2023 Became a member of the Rare Disease Diversity Coalition and are acting members of theClinical Trials
94、Working Group Amicus Public Policy lead co-chaired the Global Genes 2023 Health Equity Summit planningcommittee.For more information,please read their published discussion:Strengthening HealthEquity for Rare Disease Patients:Benefits and Challenges of Decentralized Clinical Trials(DCT)Amicus moderat
95、ed a panel on Diversity and Equity in AI and Healthcare at the annual meetingof the Alliance for Artificial Intelligence in Health Care alongside industry and FDA experts Continued to advance our support for diverse rare disease clinical trials through work withour internal Diversity in Clinical Tri
96、als Working Group to identify vendors and strategies forstrengthening trial diversity The P&PA team,LIFTED Employee Resource Group(ERG),and the Diversity in Clinical TrialsWorking Group co-hosted a global Lunch&Learn on Understanding Diverse Rare DiseasePatient Journeys with diverse rare disease pat
97、ients and health care providers,followed by aninternal roundtable with Amicus senior leadership on developing best practicesCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report17Safety of Clinical TrialsAs a patient-centric and science-driven organiz
98、ation,we must ensure that every decision we make is fully compatible with the imperatives of patient safety and data integrity.Without these commitments,our science and work would be without value.Ethical Clinical TrialsWe are committed to protecting the rights and well-being of all participants enr
99、olled in Amicus clinical trials and follow all review and approval procedures required by applicable laws and regulations before initiating clinical trials.All trials are conducted in full conformity with Good Clinical Practice(GCP)standards and the oversight of a qualified institutional review boar
100、d or independent ethics committee.We conduct safety monitoring for our clinical trials and comply with adverse event reporting requirementsAmicus is subject to external audits by health authorities to verify we comply with ethical standards and applicable laws and regulations.Recent FDA,MHRA,and Hea
101、lth Canada inspections in Amicus facilities have resulted in no significant findings(VAI or OAI).Additionally,we conduct our clinical activities to the highest standards and have had no legal proceedings associated with these activities.SASB:HC-BP-210a.1;SASB:HC-BP-210a.2Commitment to Patient Commun
102、ities of Discontinued Development ProgramsEven where a clinical program does not support continued development,we continue to support the patient communities and developments in that area to enable others to progress treatments.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmic
103、us Therapeutics2024 ESG Report18Product QualityAmicus if fully committed to developing and delivering quality therapies to patients it is our promise and duty to the rare disease communities we serve.Our ApproachOur Quality culture enforces doing things right the first time,every time,as we strive t
104、o deliver continued high quality,safe,and effective products to patients around the world.To that end,we believe that Quality is attained through living the values of personal integrity,innovation,compassion,and excellence.In order to fulfill our promise of product safety and quality to our patients
105、,through our Quality Management System(QMS),we are dedicated to meeting customer requirements by complying with the applicable laws,regulations,international standards,laboratory accreditation,and collective good practice,quality,manufacturing,and safety guidelines(GxP),as governed by health authori
106、ties.Our commitment to quality extends to all employees,including full-time,part-time,contractors,and consultants who perform work responsibilities at Amicus,and are all required to comply with our labor and safety standards included under the Amicus Code of Conduct.We also require all suppliers to
107、adhere to these standards as well as FDA enforced regulations,like the Drug Supply Chain Security Act(DSCA),and to complete mandatory yearly pharmacovigilance training.Current Good Manufacturing Practices(cGMP)Patient safety remains paramount when manufacturing and distributing our products.While we
108、 rely on contract manufacturers to supply our products and product candidates,Amicus has experienced personnel who oversee our contract manufacturers,and who have implemented the appropriate controls to ensure the quality of both our active biopharmaceutical ingredients and final drug products,and i
109、mportantly,ensure we comply with current Good Manufacturing Practices(cGMP).Oversight and Risk ManagementThe Science and Technology Committee of the Amicus Board of Directors oversees risk management in the areas of product quality and safety,GxP,and pharmacovigilance.They are also strategic in revi
110、ewing,evaluating and advising the Board on Amicus overall manufacturing strategy to ensure that we make well informed choices in the investment in manufacturing capabilities and secure appropriate levels of drug supply and drug product.Employee TrainingThe Amicus product and quality training policy
111、applies to all employees,contractors,and consultants.Employee training within the Amicus QMS includes all areas of GxP.Quality AuditsEvery aspect of the Amicus QMS,including all internal systems and vendors,receive routine quality audits across all areas of GxP.Company OverviewEnvironmental Stewards
112、hipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report19UN Sustainable Development GoalsEmployeesAt Amicus,our goal is to develop an atmosphere where employees can contribute to winning teams,lead important and meaningful initiatives,and be inspired by a diverse group of talented leaders a
113、nd colleagues.In this SectionOur Responsible Business Leadership Development and Learning Programs Career Development Plans Building an Engaged and Inclusive Workforce Employee Involvement in the CommunityAmicus Therapeutics2024 ESG Report19Company OverviewEnvironmental StewardshipPatientsEmployeesG
114、overnanceCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report20Our Responsible BusinessWe are a Rare company,full of passionate entrepreneurs,striving to be champions of the rare disease community.Our transparent,inclusive,and collaborative culture g
115、ives employees the tools and resources to grow personally and professionally while ensuring we can meaningfully engage with the global rare disease patient community.We are committed to giving back to the communities where our employees live and work through volunteer opportunities,charitable contri
116、butions,and connecting with individuals and families affected by serious illnesses.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report21Talent Pipeline Development StrategyEnriching our Employees and Promoting the Right Talent from WithinAs a biotec
117、hnology company,we recognize we are often required to fill roles that are highly specialized or warrant a specific educational background or skillset.We work hard to ensure we do our due diligence to attract and hire the right people,with the right technical skills,in addition to offering employees
118、a robust career and leadership development toolkit,so that we can develop,promote,and retain our top talent for many years.Through our succession management planning we have effectively promoted from withinforseveral key positions.SASB:HC-BP-330a.1Global Leadership Development ProgramTo ensure ourin
119、dividual contributors have the confidence and clarity on how to develop leadership skills,we launched the Self Empowered Leadership program that included a Learning Practices Inventory assessment for all individual contributors.In 2023,we continued to train our people leaders on the Leadership Chall
120、engeto ensure leaders are demonstratingand practicing exemplary leadership.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report22Leadership Development and Learning ProgramsWithin the Global Leadership Development program:95%Individual contributors h
121、ave been trained thus far and we will continue to train the individual contributor population throughout 20248Global workshops completed3,928Total Global Leadership Development Program training hours completed by employees98%People managers have been trainedthusfarandwe will continue to trainthe rem
122、aining people managers throughout20249Globalworkshopscompleted2,704Total Global Leadership Development Program training hours completed by employees“The Self-Empowered workshop held in Japan was a full-day course.It was an engaging moment to interact with the majority of the employees(there are more
123、 individual contributors than people leaders in Japan).I realized the importance of leadership in Amicus.Whats more,I started to implement the knowledge into my daily working practice and personal life.Thank you!”“This training allowed me to pause and think about how I am putting myself out there,ho
124、w others may be perceiving me,whether I am prioritizing what is most important to me,and what I should be doing to get where I want to be.It was a very useful checkpoint,as it happened about half-way into the business year.”Key Talent Development ProgramWe completed our Key Talent/High Potentials an
125、d Critical Roles review as part of our annual Talent Review process,identifying Key Talent plus successors for all critical roles and ensuring development plans are in place for all critical role successors.Key Talent participants are involved ina formalDevelopment andMentoring program,with senior-l
126、evel Key Talent mentoring early-career Key Talent.1,152Total Key Talent Development&MentoringProgram training hours completed by employeesCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report23Career Development PlansMission-Focused BehaviorsIn 2019,b
127、uilding on our founding beliefs,we put in place Mission-Focused Behaviors(MFB)to define and shape culture,drive performance and innovation,inform development and growth,and attract and retain the best talent.This was transformational for our culture leading to advancements in design thinking and gro
128、wth mindset.We reimagined our performance management process to measure the what and the how,rewarding those who role-model our Mission-Focused Behaviors.Through Extensive Employee-Driven Workshops,We Shifted from Traditional Thinking and:Embedded the leadership traits of our culture(mission,integri
129、ty,performance,and innovation)into our career development strategy.Altered the way we conduct performance management with these commondrivers as the foundation.Continued our approach to performance management,including thecontinuation of afeedback culture to drive results,and a fair systems-based me
130、asurement process that captures performance data.We measureemployees on the what/OKRs and the how/MFBs at both the mid-year andyear-end,and we share 360 feedback with each other annually as a part ofthe performance management process.InnovationWe try new things,learn,and grow every day.MissionWe alw
131、ays put our patients first.PerformanceWe are results-oriented,high performers.IntegrityWe do things the right way.Amicus LearnsWe leverage and curate online learning content for all employees,including over 16,000 courses from LinkedIn Learning,of which we have integrated into the Amicus Learns plat
132、form to encourage employee professional development and informal connection.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report24Employee Recruitment,Engagement,and RetentionWe take pride in the talented individuals that comprise our organization an
133、d work hard to foster their growth and development.We leverage their capabilities and expertise to provide a corporate culture that drives performance and ultimately attracts,energizes,and retains critical talent.We are united by our commitment to building a highly engaged and inclusive corporate cu
134、lture,driven by our Mission-Focused Behaviors,as we strive to be champions of the rare disease community.Lead from Within:Reimagine,Rediscover,and ReinventIn support of our Innovation behavior,we empower employees to lead efforts to Rediscover,Reimagine,and Reinvent Amicus by developing prototypes t
135、hat can be tested and implemented on a large scale across the company and will position us well for the future.After Action ReviewsIn the spirit of having a growth mindset and continuous improvement,we launched training for the organization on After Action Reviewsto ensure we build these into our ev
136、eryday performance culture.Growth Mindset CultureThe Resource Marketplace,an idea that stemmed from our Design Thinking Initiative,gives employees the opportunity to submit their ideas for cross-functional programs,then participate in each others pilot projects to take a collaborative approach to in
137、novation.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report25Employee Recruitment,Engagement,and RetentionA Great Place to WorkIn 2024,we were certified as a Great Place to Work(GPTW)company.We engaged our workforce on a group-by-group level to tak
138、e a deeper dive into our GPTW survey results to provide greater transparency into employee responses and discuss how we plan to incorporate their feedback into the future of Amicus.Survey results reveal that Amicus employees:Feel high personal satisfaction in their job,wherepeople are proud of their
139、 work and what they contributeto the community.Feel they are treated fairly no matter race,ethnicity,age,gender,or sexual orientation.Believe their work has meaning and feel a senseof accomplishment.Feel that Amicus is a safe place to work fromevery aspect90%of employees at Amicus Therapeutics say t
140、hat it is a great place to work compared to 57%of employees at a typical U.S.-based company90%57%Amicus TherapeuticsTypical CompanySince the last time the GPTW survey was completed in 2020,improvement was shown in 21 of the 25 survey focus areas.The global participation rate also increased,from 80%i
141、n 2020 to 90%in 2024.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report26Employee Recruitment,Engagement,and RetentionTalent Recruitment and Retention EffortsWe invest a significant portion of resources to attract,develop,and retain the right talen
142、t to help us succeed in delivering on our mission for people living with rare diseases.In an effort to maintain employee overall job satisfaction,we place an emphasis on providing our employees with the tools and opportunities to grow personally and professionally within their careers.Fair and Effec
143、tive InterviewingWe offer training to all hiring managers through LinkedIn Learning to help individuals identify and implement fair and effective interviewing practices into their hiring process.At Amicus,We Offer:Tuition reimbursement Mentorship and internship programs Leadership development progra
144、ms for managers andindividual contributors An employee referral program Opportunities to spearhead part-time projects that allowemployees to build new,differentiated skillsets whilemaintaining their current role Robust career toolkits and performance planning guidesdesigned to unleash career develop
145、ment potential Executive coaching to support advancement of Amicuskey talent Recognition programs to support and thank colleaguesHealthy Work Life Integration:Substantial time-off policy allows employees to rechargeand spend time with family and friends Family Days,days beyond the allotted vacation
146、Half-day summer Fridays Company shutdown during the year-end seasonTuition Assistance Program(TAP)Amicus believes in a strong culture of innovation,learning,and development.Personal enrichment strengthens the skills and knowledge of the employee and enhances Amicus internal talent pool.The Amicus Tu
147、ition Assistance Program(TAP)encourages and supports employees enrolled in accredited institutions in courses that relate to their current position or future career pathways.Over the years Amicus has supported numerous employees in furthering their education.Partnerships with Educational Institution
148、s As part of our commitment to supporting,nurturing,and developing the next generation of talent,and strengthening our university relations,Amicus works closely with Rutgers University to support students pursuing careers within the life sciences field.Amicus has partnered with the Rutgers Institute
149、 for Pharmaceutical Industry Fellowships to recruit individuals with a Doctorate of Pharmacy or Medicine and help them further their education through real world industry experience and work in clinical research.Amicus is also an original supporter of the Rutgers Genetic Counseling Masters Program a
150、nd has provided a modest scholarship each year since its inception for an out-of-state Genetic Counseling student to attend the program.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report27Employee WellnessWellness Program at AmicusTo support and pr
151、omote efforts that lead to living a healthy lifestyle,Amicus offers a variety of resources and services.Our Wellness Program was established to focus on improving employee health and well-being in the areas of physical activity,healthy eating,and mental health.We have incorporated a health and welln
152、ess program into our employee benefits package to help educate,motivate,and assist employees in adopting healthy choices and behaviors.Wellness Driven WorkspacesWhen it comes to designing and developing our offices,we made it a priority to incorporate design elements that encourage,energize,and insp
153、ire our employees to perform to their highest potential,while also promoting overall employee wellness.Within our office spaces around the world,we have implemented:Wellness and nursing rooms Ergonomical workstations that include height adjustabledesks suitable for standing Active workplace design t
154、hat promotes collaborationand walkability to key locations around the office Outdoor spaces and access to natural daylight Integration of nature throughout the facility such as foliageor“green walls”and the incorporation of natural materialsEmployee Assistance ProgramWe are proud to provide our empl
155、oyees and their families with access to a comprehensive Employee Assistance Program which provides confidential support services for a wide range of needs.Mental Health First AidersWeve maintained over 50 trained Mental Health First Aiders globally and are actively recruiting more volunteers through
156、out the company.Our Mental Health First Aiders are trained to identify the signs of mental health issues and assist individuals by guiding them toward further support,whether thats through self-help resources,company resources,like our Employee Assistance Program,or external resources such as local
157、Healthcare Practitioners.Best Self Training ProgramInvented by our employees for our employees through our Design Thinking Initiative,the Best Self training program offers participating individuals with funding to help them improve their overall well-being and bring their Best Self plans to life.We
158、continued our Best Self initiative in 2023 with 272 participants globally.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report28Human CapitalWe strive to have a meaningful impact on organizational performance and enable a competitive advantage throug
159、h our people.We have over 500 employees across the U.S.and select international countries who are key to advancing our programs and who contribute to our mission-focused culture with passion,dedication,and excitement for the work that we do.Our Board of Directors and senior leadership are committed
160、to our broad Talent philosophies and practices,to create value and support our mission.Attracting and retaining talented team members and creating an exceptional work environment is an integral part of our competitive strategy and advantage in driving long-term value for the organization.To that end
161、,the Compensation and Leadership Development Committee and the full Board review our Talent programs and processes on a regular basis,including our talent pipelines,retention rates,workplace culture,inclusion and engagement,and any risks to those.Voluntary and Involuntary Turnover RatesVoluntary and
162、 involuntary turnover rates across all levels(executives/senior managers,mid-level managers,and professionals)are in alignment with,or lower than,the industry average.SASB:HC-BP-330a.2Gender Breakdown by Level(as of December 31,2023)MaleFemaleEntry Level/Non-ManagerSenior Level/VP and AboveMiddle Ma
163、nagement42%58%Global Gender Population84%16%54%46%64%36%Amicus management reviews pay parity bi-annually in an on-going endeavor to ensure equal treatment across the organization for equal work and makes market adjustments as needed.The Compensation and Leadership Development Committee does the same
164、 for all levels of the Amicus workforce.80We continue to attract excellent candidates and hired80 people globally in 2023.Executive CommitteeCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report29Diversity,Equity,and InclusionDiversity,Equity,and Incl
165、usion(DEI)at Amicus is about creating an environment that supports bringing the authentic“you”to the workplace.Our unique experiences,backgrounds,and range of cultural perspectives enrich how we approach opportunities,pushing ideas as far and as fast as possible with patients always our top priority
166、.Employee expertise,intelligence,and creativity drives our innovation and our passion and commitment to excellence.Our Commitment to DEIStrengthen our culture of inclusivity by delivering on our diversity,equity,and inclusion programs.Ensuring equal opportunities for all inhiring for open rolesConti
167、nuously evaluate compensation practices toensure pay parityEstablish external partnerships with universities and organizations to create recruiting channels into AmicusOur“Three Pillars of DEI”are interwoven into our Amicus culture and expand one person,one word,and one act at a time.For our employe
168、es,these three pillars are a touchstone for inspiration,guidance,and encouragement.PEOPLEPATIENTSPHILANTHROPYEmbed DEI into activities of our business units,the Amicus Belief Statement,and Mission-Focused BehaviorsEstablish external partnerships withuniversities and organizations to create recruitin
169、gchannels into AmicusEnsure equal opportunities for all inhiringfor open rolesCreate patient education to impact health literacyAddress the impact of socioeconomics and access through advocacyWorktowards global accessto treatments for patientsSupport non-profits that impact communitiesInvest in the
170、next generation of innovators through partnerships with STEM programsBuild awareness of rare diseases in our communitiesCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report30Employee Resource GroupsBuilding from our ongoing commitment to diversity,eq
171、uity,and inclusion,we launched Employee Resource Groups(ERGs);voluntary,employee-led groups designed to foster a diverse and inclusive workplace.Groups exist to provide support and help in personal or career development,business goals,and to overall create a safe space where employees can bring thei
172、r whole selves to the table.Holistic ApproachRecognizing that diversity and inclusion are multifaceted issues,tackling these issues holistically increases engagement and support for all underrepresented groups within business.To do this,we believe in addressing the concerns and needs of our diverse
173、employees honestly and head-on,which will increase equity for all including Blacks,Latinx,Asians,Native Americans,LGBTQ+,women,veterans,and people with disabilities.We pledge to support a more inclusive culture to impact our employees,our communities,and society.LIFTED,A BLACK ERGLeaders of Inclusiv
174、ity Fostering Talent,Empowerment,&DiversityLIFTEDLeaders of Inclusivity Fostering Talent Empowerment&Diversity A Black ERGPRISMCreate and maintain a safe,inclusive,and equitable environment for LGBTQ+employees and patientsWILWomen in LeadershipALL INAsians Learning Leadership&InnovationserveSERVESup
175、port&Engagement of Reservist&Veteran EmployeesDRAWDisability&Rare Advancement in the WorkplaceGREENMake a difference to our global environment,ensuring there is a future for our communities,our patients,and ourselvesCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeut
176、ics2024 ESG Report31Corporate Social ResponsibilityWe have a shared purpose of improving public health,patient experiences,and outcomes with a focus on educational,advocacy,and access initiatives related to the disease areas in which we focus our development and therapeutic programs.We have proudly
177、developed a corporate responsibility initiative,Healing Beyond Disease(HBD)to reinforce our commitment to the rare disease community.Healing Beyond DiseaseThe rare disease community always has a voice within Amicus.Healing Beyond Disease is our unique promise to further serve the needs of the rare d
178、isease community in extraordinary ways.Lunch&LearnsAn educational mainstay since the earliest days of the company,the Healing Beyond Disease Lunch&Learn series is part of our longstanding commitment to educate and inspire Team Amicus by hearing the patient voice directly and amplifying our care,conn
179、ection,and compassion for the rare disease community.Employee Resource Groups Supporting the Rare Disease CommunityThroughout 2023,our Employee Resource Groups(ERGs)worked hand-in-hand with Healing Beyond Disease offering numerous volunteering initiatives to our global employees to provide resources
180、,supportive services,and advocacy to our community members in need.5 Volunteering Events Hosted in Collaboration with ERGs and HBD throughout 2023:LIFTED with non-profit partner,Minds Matter:Assembled college care packs for first generation or low-income college students to provide them with the org
181、anizational and study tools to succeed.GREEN with non-profit partner,Boys and Girls Club of Mercer County:Assembled engineering STEAM kits to provide hands on learning opportunities around sustainability,engineering,and renewable energy.DRAW with non-profit partner,Hole in the Wall Gang Camp:Assembl
182、ed writing kits to support children living with serious illnesses as they enjoyed the spirit of childhood at summer camp.SERVE with non-profit partner,Home Base:Assembled health and fitness kits for Veterans to aid them in taking control of their physical well-being and manage the invisible wounds o
183、f war.HBD with non-profit partner,International Rescue Committee Assembled welcome home kits for immigrant and refugee families to provide them with the resources to resettle into their new homes.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report32
184、Employee Involvement in the CommunityAmicus Global Month of ServiceSince its founding,Amicus has had a strong focus on volunteering and giving back.Volunteering brings people together and fosters a sense of community.In 2023,Healing Beyond Disease hosted its 2nd Annual Global Month of Service to enc
185、ourage employees to collaborate and give back to their local communities.During the Global Month of Service,Amicus teamed up with key partner Building Impact to offer volunteer opportunities to our employees worldwide.Building Impact is a non-profit organization that works with companies and groups
186、to facilitate local volunteering initiatives that are designed to strengthen and make a positive impact for communities in need.Throughout the month,Amicus and Building Impact hosted three virtual service opportunities with more than 140 employees volunteering across the globe.1,000Lives Impacted143
187、Volunteers Engaged Globally4.95Volunteer Experience Rating$21,000Total Contributions to the Community2023 Charitable Giving(As of December 31,2023)United StatesInternational64Total number of contributions61$1,980,516Total amount of contributions allocated$706,417$1,879,666Total amount given to rare
188、disease patient advocacy organizations(PAOs)$355,429$100,850Total amount given to community nonprofits organizations,which also includes medical/educational institutions$350,988VolunteerismAmicus offers employees the opportunity to take three paid volunteer days each year(24 hours)so they can spend
189、time giving back to our communities and contribute to local initiatives.In 2023,employees donated time for numerous volunteer activities,including raising money for unhoused communities,working at local food banks,participating in holiday gift drives,building kits,and working with family-to-family p
190、rograms.511hrsVolunteer hours logged by U.S.employees37Community support programs in which Team Amicus has participatedCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report33UN Sustainable Development GoalsGovernanceOur compliance culture is driven by
191、 integrity and a commitment to never prioritize short-term profit over sustainable long-term success.In this SectionEthical Business Practices Culture of Compliance Corporate Governance Enterprise Risk Management Data Security and Privacy CybersecurityAmicus Therapeutics2024 ESG Report33Company Over
192、viewEnvironmental StewardshipPatientsEmployeesGovernanceCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report34Ethical Business Practices and MarketingAmicus Code of ConductWe believe good corporate governance is important to ensure that Amicus is man
193、aged for the long-term benefit of our stakeholders.We have adopted a Code of Conduct,which applies to all of our officers,directors,and employees,corporate governance guidelines and updated charters for our Audit and Compliance Committee,our Compensation and Leadership Development Committee,our Nomi
194、nating and Corporate Governance Committee,and our Science and Technology Committee.These revised corporate governance guidelines and committee charters,reviewed and updated at least every three years,as well as our Code of Business Conduct which is reviewed and certified annually,provide a framework
195、 for the comprehensive oversight of designated risk areas by the Board and its Committees and is an important interface with our Enterprise Risk Management Program.For a full breakdown of the Amicus Compliance program and our commitment to ethics,please visit our website here.Year at a Glance Amicus
196、 adopted a global policy on Modern Slavery with a commitment to implementing and enforcing effective systems and controls to ensure Modern Slavery is not taking place anywhere in our business.Awareness of modern slavery risks amongst Amicus employees has also been increased with the introduction of
197、the policy and associated training We appointed a senior leader in the organization to have oversight of compliance We commenced work on including questions regarding modern slavery risk in supplier due diligence and the inclusion of specific contract language on such risks with certain suppliersFur
198、ther information on the Amicus Therapeutics UK Limited Modern Slavery Act Statement can be found here 7A M I C U S T H E R A P E U T I C S /C O D E O F C O N D U C T /C O M M I T M E N T T O P A T I E N T S 2.COMMITMENT TO PATIENTSAt Amicus,everything we do is done first and foremost to help improve
199、 the lives of people living with a rare disease.This means understanding patients medical needs through active listening,innovation through best-in-class science,delivering a safe and consistent supply of product,engaging in truthful and non-misleading communications with healthcare practitioners ab
200、out our products,and transparently disclosing our science-driven relationships with those practitioners to patients and the public.2.1 Patient Advocacy OrganizationsPatients and the advocacy organizations that represent them are at the heart of everything we do.It is the mothers,fathers,sons,and dau
201、ghters the real people who live with rare disease who are the focus and beneficiaries of our work.To do that great and meaningful work we need to be great listeners and learners.We need to understand the true burdens of the individuals,families,and caregivers living with the rare diseases we seek to
202、 alleviate,and to grasp the medical needs of those rare disease communities.That understanding in turn informs and energizes everything we do.Such is the foundation and premise for our interactions with patient advocacy organizations.At the same time,we are committed to complying with the global pha
203、rmaceutical laws and industry codes that regulate our interactions with patient advocacy organizations and have developed policies and SOPs to help guide those interactions.Associates who interact with patient advocacy organizations on behalf of Amicus must comply with those policies and SOPs which
204、are trained upon and available on the Amicus intranet under“Corporate Operations/Compliance/Policies&SOPs.”2.2 Patient SafetyAs a patient-centric and science-driven organization,we must ensure that every decision we make is fully compatible with the imperatives of patient safety and data integrity.T
205、hese imperatives apply at every stage during the lifecycle of our products.During research and development,the safety of patients participating in our clinical trials is paramount,and we conduct such trials in full conformity It is the mothers,fathers,sons,and daughters the real people who live with
206、 rare disease who are the focus and beneficiaries of our work.16A M I C U S T H E R A P E U T I C S /C O D E O F C O N D U C T /C O M M I T M E N T T O C O M M U N I T I E S 5.COMMITMENT TO COMMUNITIES Amicus aims to make a positive difference for the communities in which it operates and with whom i
207、t interacts.5.1 Charitable Contributions and Donations Amicus is pleased to support legitimate and worthy causes in the community when requested by charitable,non-profit organizations.To ensure that all funding we provide,in cash or kind,is in line with our mission,values,and the law,we have impleme
208、nted policies and SOPs which are trained upon and available on the Amicus intranet under“Corporate Operations/Compliance/Policies&SOPs.”5.2 Media RelationsAs a public company,Amicus is subject to rules and guidelines concerning our public disclosures of information.We communicate honestly,accurately
209、,and timely with shareholders,securities analysts,and the media,avoiding selective disclosures that would give some parties an unfair advantage.Only certain individuals are authorized to speak on behalf of Amicus.5.3 Protecting the Environment Amicus is committed to operating in a way that respects
210、and protects the environment wherever we are located.We will not compromise environmental values for profit or production.We respond truthfully and responsibly to questions and concerns about our environmental actions and the impact of our operations on the environment.Amicus has developed policies
211、and SOPs on this topic which are trained upon and available through the Amicus intranet under“Common Internal Links/MasterControl.”14A M I C U S T H E R A P E U T I C S /C O D E O F C O N D U C T /C O M M I T M E N T T O S H A R E H O L D E R S4.COMMITMENT TO SHAREHOLDERSWe protect the investments m
212、ade by shareholders in our business by not putting those investments at risk.4.1 Pharmaceutical Laws and RegulationsOur goal is to create first-in-class and best-in-class treatment options for people living with rare disease.It is the passion that unites us and inspires us at work.To accomplish this
213、 goal,we must wisely and expertly put to work the investments we get from our shareholders.This includes making sure those investments are never put at risk by legal proceedings such as government investigations that could result in large fines and other sanctions that could compromise the sustainab
214、ility of our company and by extension our commitments to patients and shareholders.To ensure the sustainability of our enterprise and to make good on our promise to patients and shareholders,Amicus is committed to high performance with high integrity,which means we comply with all pharmaceutical law
215、s and regulations in every phase of our work from research and development,to manufacturing,to marketing,promotion,and distribution.4.2 Anti-Bribery and Anti-CorruptionOur commitment to shareholders includes complying with all anti-bribery laws and competing solely on the merits of our products whil
216、e never engaging in any form of bribery or corruption regardless of local practice or custom.Such laws include the US Foreign Corrupt Practices Act and the UK Bribery Act.It is important to know that in addition to these important laws almost every country in the world has its own anti-bribery law,s
217、o no matter where in the world you conduct business there is a law prohibiting bribery that applies to you.While the language in these laws may vary,their central message is always the same:it is against the law to offer anything of value to win or retain business.Amicus has developed policies and S
218、OPs,including a Global Anti-Bribery Policy,which are trained upon and available on the Amicus intranet under“Corporate Operations/Compliance/Policies&SOPs.”4.3 Fair Competition and AntitrustWe compete for business aggressively,honestly,and solely on the merits of our products.Fair competition laws p
219、rotect consumers from inflated prices that can arise from unfair business practices such as agreements between competitors.10A M I C U S T H E R A P E U T I C S /C O D E O F C O N D U C T /C O M M I T M E N T T O E M P L O Y E E S A N D O U R C O M P A N Y3.COMMITMENT TO EMPLOYEES AND OUR COMPANY Th
220、e foundation of our commitment to one another is based on respect.We treat each other respectfully,the company treats us fairly,and we act in the companys best interests through our dedicated work and by safeguarding the companys records,assets,and reputation.3.1 Discrimination and HarassmentWe each
221、 play an important role in creating an open and inclusive workplace,where every individual is able to fully contribute to our success.Building a talented and diverse workforce strengthens our company and its competitive advantage.To champion these important values,we must:Treat others fairly and wit
222、h respect;Avoid actions that could be considered bullying or harassment;Focus solely on a persons qualifications,abilities,experience,and performance if we are responsible for hiring,firing,compensation,promotions,or employee discipline.Amicus has developed policies and SOPs on this topic which are
223、trained upon and available on the Amicus intranet under“Corporate Operations/Human Resources/HR Policies&Procedures.”3.2 Labor Practices Upholding human rights is a direct reflection of our commitment to ethical business practices.Amicus is committed to providing all Associates with fair and competi
224、tive wages in exchange for high performance conducted with high integrity.We comply with the wage and labor laws of every country in which we operate,and will never use child or forced labor in our operations.Should we become aware of suppliers who violate these principles,we will terminate our rela
225、tionship with them as their association with us is a reflection on our ethics.If you have reason to believe anyone we work with is violating these standards,please inform the Human Resources Department at once.Amicus has developed policies and SOPs on this topic which are trained upon and available
226、on the Amicus intranet under“Corporate Operations/Human Resources/HR Policies&Procedures.”Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report35Global Training on Policies&ProceduresYearly training on Amicus policies,standard operating procedures(SOP
227、s),and the law,is conducted by each employee consisting of a mix of live in-person training,interactive online training,as well as policy/SOP read and acknowledge supplemented by mandatory comprehension test questions.100%of all Amicus employees have received training on the Amicus Global Code of Co
228、nduct100%of full-time employees provided written or digital acknowledgment of the Global Code of Conduct12 Global Policies covering all aspects of commercial marketing practices,including but not limited to:Code of Conduct,Anti-Bribery,Privacy,Conflicts of Interest,Advisory Boards,Charitable Contrib
229、utions,HCP Interactions,Pre-Approval Interactions,Independent Medical Education,Modern Slavery Policy9 International Policies,which more specifically address key topics in International Pharmaceutical Codes47 Country-specific SOPs,which more specifically address key topics in local country law“What
230、inspired me about Amicus was the initial concept which were seeing true nowThe truth takes time and youve got to be patient.And it is hard work Focus on the fact that the truth sees ultimately the right side and always stay on the right side of truth.”Mike Raab,Chairman of the Board on the approval
231、of our treatment for late-onset Pompe diseaseCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report36Compliance ProgramCulture of Business Ethics and ComplianceAmicus is committed to maintaining a culture of business ethics and compliance,and strongly
232、believes that a good culture of ethics needs to be visibly and consistently role modeled and reinforced,first and foremost,by the Senior Leadership Team,by all of management,and ultimately,by the entire organization.This was our intent when building our Integrity Leadership Program.We realized that
233、when pressure mounts and employees need to make a decision regarding whether to take action,theyre more likely to base decisions on the cues of their workplace culture than base them off words in the Code of Conduct.Thats why at Amicus we thoughtfully constructed a holistic culture of compliance tha
234、t is lived and breathed daily by everyone in the organization.Whistleblower Policy&Global Reporting HotlineSpeaking up is crucial to our culture and to our long-term sustainability.It is because we care about our employees,patients,customers,and business partners that we take reporting concerns so s
235、eriously.Amicus maintains a whistleblower policy and anonymous global reporting hotline available to all employees.We assure that all hotline reports are confidential and guarantee non-retaliation,as outlined in the Global Code of Conduct and every Global Policy.Employees can report via the hotline
236、anywhere throughout the world and through multiple avenues such as the toll-free hotline phone numbers,secure external and internal websites,and email.Our promise to our employees is that if an individual,regardless of title or role,is determined to have retaliated against an Associate who has truth
237、fully and in good faith reported a potential violation,Amicus will take appropriate disciplinary action against that retaliator,up to and including termination of employment as permitted by local law.Our compliance program has been developed in accordance with the laws applicable to our industry,the
238、 Program Guidance for Pharmaceutical Manufacturers published by the Office of the Inspector General of the U.S.Department of Health and Human Services,and the PhRMA Code of Interactions with Healthcare Professionals.Our Amicus Compliance Program Includes:Global Chief Compliance and Risk Officer,repo
239、rting directly to the CEO,and Global Risk Committee to ensure senior leadership visibility of key risks Amicus Compliance Engine(ACE),which approves all commercial activities and continuously monitors and audits approved activities to verify compliance Written standards of conduct,policies,and pract
240、ices that document the companys commitment to compliance.Mandatory training and educational materials that must be acknowledged by all employees Enterprise Risk Management Program to identify and address risks.Risk Assessment is conducted annually to ensure robust controls for all key risks Enforcem
241、ent of compliance obligations through guidelines that include disciplinary action for noncompliance Mechanisms to investigate and respond promptly and properly to reports of noncompliance,including processes to initiate corrective measures“Its all about people and working together towards a common g
242、oal.When the culture of a company,whether its in biotech,pharma or any other industry,is positive,it has a tremendous ripple effect.”Glenn Sblendorio,Chair Audit&Compliance Committee on our culture of ComplianceCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics20
243、24 ESG Report37ESG GovernanceThe company closely monitors proposed and enacted ESG and emissions regulations around the globe.We believe our proactive approach and the diverse composition of our group positions us well to address regulations in this emerging field.Nominating and Corporate Governance
244、 Committee Oversees Amicus ESG strategy,policies and initiatives at the Board level Reports to the Board periodicallyExecutive Leadership Team Oversees the development of the ESG strategy and progress of Amicus ESGWorking Group in alignment with the input of the other committeesAudit and Compliance
245、Committee Oversees financial risk,Cybersecurity and ERM ProgramScience and Technology Committee Oversees product quality and safety and provides input intoenvironmental and safetyCompensation and Leadership Development Committee Monitors human capital and DE&IESG Working Group Responsible for execut
246、ion of the ESG strategy and works with business leadersthroughout the organization to drive implementation and internal stewardship Led by Chief Legal Officer who provides updates to Amicus Global RiskCommittee and Nominating and Corporate Governance CommitteeAmicus Corporate Governance At a GlanceB
247、est Practices Ongoing shareholder engagement program Diverse Board Board Oversight of ESGIndependence Strong and active Board Chairman Other than our President&CEO,all other directorsare independent Independent directors in Audit and Compliance Committee,Nominating and Governance Committee,and Compe
248、nsationand Leadership Development CommitteeAccountability Clawback Policy Annual board and committee self-evaluations Prohibition against hedging transactions Stock Ownership PolicyOur board of directors have corporate governance guidelines to assist in the exercise of its duties.Each of our committ
249、ees operates under a written charter setting forth functions and responsibilities of the committee,copies of which are available on our website.For more information on our directors and corporate governance,please see our Proxy Statement.Company OverviewEnvironmental StewardshipPatientsEmployeesGove
250、rnanceAmicus Therapeutics2024 ESG Report38Board of DirectorsThe Board is committed to ensuring its members possess the appropriate skills,experience,expertise,qualities,and commitment necessary to meet the ever evolving needs of the business while maintaining integrity,honesty,and high ethical stand
251、ards.To this end,the Board engages in periodic self-assessments and annually reviews a skills matrix designed to highlight diversity,demonstrate the complementary skills of its members,and identify areas of focus to look for in future nominees.Beginning with our Board of Directors and our Senior Lea
252、dership Team,we are committed to long-term value driven by the pillars of governance,social responsibility,and integrity across all we do,including employee engagement,clinical and regulatory operations,and eventual access to medicines for patients.Oversight of our Risk Management Program is robust,
253、and includes quarterly review by both our internal Global Risk Committee composed of our senior leaders and our Audit and Compliance Committee,which is primarily responsible for reviewing and advising the full Board on all material risks and developments.The other board committees each have oversigh
254、t into specific risk areas.Within this risk management framework,we seek to build a sustainable,vibrant risk mitigation culture,which places emphasis on how we do things as much as what we achieve.We recognize the sustainability of our company is linked to our ability to understand and engage all st
255、akeholders in a consistent and meaningful manner,as well as manage risks throughout the organization.Board Diversity AwardIn 2023,we were recognized by The Forum of Executive Women as a 2023 Champion of Board Diversity for having a Board of Directors where women account for more than 30%.The Forum o
256、f Executive Women announced that 37 of the top 100 public companies in the Philadelphia area share this recognition and we are one of the eight companies recognized for the first time.89%Board Independence61.9yrsAverage Age9.3yrs Average Tenure55.5%Overall Board Diversity*Director Diversity3 Female
257、1 Veteran Status 1 African American or Black*Diversity includes gender,race,and veteran status“When I hear about an approval of a new drug for a rare disease,I can just imagine the excited face of a patient,their parents and other loved ones that finally have hope that something can make a differenc
258、e,giving a patient who may have suffered for years the quality of life that they deserve.Margie McGlynn,Board Director,Chair Compensation&Leadership Development CommitteeCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report39Our Enterprise Risk Manage
259、ment Program and ESG OversightThe Board,its committees,and our Senior Leadership Team drive and oversee risk reduction through our Enterprise Risk Management Program,which includes established periodic reporting and open lines of communication.The following chart illustrates the oversight responsibi
260、lities by the Board for areas in the committees areas of expertise under the Enterprise Risk Program.Board of DirectorsThe full Board has primary responsibility for risk oversight.ManagementManagement is responsible for the enterprise risk assessment process and the day-to-day management of risks.Gl
261、obal Risk CommitteeComprised of department leads,co-chaired by Chief Compliance and Risk Officer and Head of Global Rare Diseases.Audit and ComplianceOversees all matters related to the ERM Program as well as financial,compliance,data privacy,and cybersecurity.Nominating and Corporate GovernanceOver
262、sees risks related to Board composition,activism,corporate social responsibility,philanthropy,and both the environmental and governance components of the companys ESG initiatives,all of which roll up to this committee for final review.Compensation and Leadership DevelopmentOversees risks related to
263、Human Capital and the social component of the Companys ESG undertakings which include:compensation,leadership development,succession planning,diversity,equity,and inclusion,and pay equity matters.Science and TechnologyOversees pharmacovigilance,safety,and risks associated with science,clinical devel
264、opment,regulatory,intellectual property,manufacturing,quality,and supply chain.Reviews,recommends,and supports N&G in evaluating environmental initiatives.Board CommitteesIn 2023,the board and the committees reviewed with management various risks and mitigation strategies,including those related to:
265、The companys initiatives related toESG and sustainability matters,includingboth newly enacted and proposedreporting requirements The controls and processes put inplace to protect employee andthird party privacy Cybersecurity and securityprograms related to our informationtechnology systems Human cap
266、ital management,such asemployee retention and recruitment Responsiveness to shareholder concerns The companys approach to evaluating itsclinical and preclinical programs Geopolitical events that could impact thecompanys operations Financial,regulatory and other auditsThe board delegates oversight of
267、 certain risks to each board committee,and each member of the executive leadership team is responsible for certain risk areas.For a summary of our risks,see Item 1A Risk Factors in our 2023 Annual Report.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG
268、Report40Data Security and PrivacyWe are committed to compliance with all global privacy laws and maintain a privacy program,including a global privacy policy,comprehensive training,and system operating procedures and controls.Data Security and Privacy ProgramAmicus maintains a cybersecurity strategy
269、 that is based on Policy,Process,People,and Technology.Amicus maintains policies and procedures to educate employees on their responsibilities when accessing computerized systems,handling of data and information,and reporting cyber events in a timely manner.Formal training on all policies and proced
270、ures is required for all employees and contractors.2023 Highlights:Vendor Risk Management with emphasis on IT resiliency and recovery capabilities Provided monthly cybersecurity awareness training to all employees and contractors to continually enable personnel to recognize and respond to cybersecur
271、ity risks Successfully tested organizations Crisis Management Plan for cybersecurity incident scenarios.Exercise engage cross-functional team executives and subject matter experts.Leveraged third party cyber security firms to assess our cybersecurity program as additional validation of the organizat
272、ions control environment Made continued improvements to the various aspects of cybersecurity life-cycle including:threat detection,preventative controls,response and recovery capabilities,metrics and reporting,training and awareness,and phishing simulationCybersecurity at a glance:0Material cybersec
273、urity events over past 5 years100%Number of employees receive data protection cybersecurity and social media trainingCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report41CybersecurityBoard OversightThe Board has delegated oversight of the Companys c
274、ybersecurity program to the Audit and Compliance Committee.The Companys Chief Information Officer(“CIO”)is allotted time to update the committee on the status of any cybersecurity events that have occurred or initiatives that are on-going,planned,or have been completed.The Chair of the Audit and Com
275、pliance Committee is then tasked with providing material updates to the board as may be necessary as part of the committees report.Company OversightThe CIO has operational oversight of company cybersecurity programs.The team consists of multiple internal cybersecurity experts,each with 15+years of e
276、xperience,and external third-party partners that provide protection,mitigation,and advisory services;including around the clock threat monitoring and response.This team is responsible for establishing company processes,brining in appropriate cybersecurity technology,and training the people of the or
277、ganization on best practices.CIOAuditBoardCybersecurity ExpertsCompany EmployeesGRCGovernance Risk CommitteeThe CIO provides regular updates to and receives updates from the Governance Risk Committee(GRC)to ensure the CIO,the Chief Risk Officer and other executives have visibility and can respond to
278、 various risks to the organization.Company OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report42Cybersecurity FrameworkThe Company believes well trained people,and pressure tested processes,supported by targeted technology,forms the backbone of a successful
279、 cybersecurity program.To that end,all company employees are subject to periodic cybersecurity trainings on how to identify potential threats and report suspicious events.Furthermore,the Company also holds table-top exercises simulating various cybersecurity incidents to ensure the processes,trainin
280、gs,and technology that are in place prove effective.For these reasons,the Company believes it is well positioned to meet the new SEC cybersecurity disclosure requirements and continue to build upon its strong record of securing the Company,its employees,its vendors and its patients confidential or s
281、ensitive information.IdentifyDetectRespondProtectRecoverNIST FrameworkPeopleProcessTechnologySecurityIntegrityAvailabilityConfidentiality Our focus on the patients and doing what is right has always been at the heart of my commitment to Amicus.In my service on the Board,I have been continually impre
282、ssed with the dedication to risk oversight to ensure all we do maximizes the opportunity for our life changing therapies to reach the patients that need them.The Board,Management,and all employees always work together in true partnership to ensure we provide the quality products our patients deserve
283、.Craig Wheeler,Board Director,Chair Science&Technology Committee,and member of Audit and Compliance CommitteeCompany OverviewEnvironmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report43Sustainability Disclosure Topics&Accounting MetricsThe Sustainability Accounting Standa
284、rds Board(SASB)is dedicated to improving the effectiveness and comparability of corporate disclosure on environmental,social,and governance(ESG)factors.The SASB index below indicates how Amicus public reporting aligns with the Biotechnology and Pharmaceuticals industry standards.TopicAccounting Metr
285、icLocation Safety of Clinical Trial ParticipantsHC-BP-210a.1 Discussion,by world region,of management process for ensuring quality and patient safety during clinical trialsSafety of Clinical Trials(p.17)Amicus Code of Conduct HC-BP-210a.2 Number of inspections related to clinical trial management an
286、d pharmacovigilance that resulted in:(1)entity voluntary remediation or(2)regulatory or administrative actions taken against the entitySafety of Clinical Trials(p.17)2023 10-KHC-BP-210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing c
287、ountriesNone.Access to MedicinesHC-BP-240a.1 Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine IndexPricing Promise and Commitment to Patients(p.14-15)Amicus AssistHC-BP-240a.2 List of
288、 products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme(PQP)Given the focus on targeted rare genetic disease medications,no Amicus products are on the WHO List of Prequalified Medicinal Products at the time of reporting.Company OverviewEnvi
289、ronmental StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report44TopicAccounting MetricLocation Affordability&PricingHC-BP-240b.2 Percentage change in:(1)weighted average list price and(2)weighted average net price across product portfolio compared to previous reporting periodAmic
290、us limits the annual price increase of our products to the Consumer Price Index(CPI)HC-BP-240b.3 Percentage change in:(1)list price and(2)net price of product with largest increase compared to previous reporting yearPricing Promise and Commitment to Patients(p.14)Drug SafetyHC-BP-250a.1 Products lis
291、ted in public medical product safety or adverse event alert databasesOur therapies are not listed.HC-BP-250a.2 Number of fatalities associated with productsNone.HC-BP-250a.3(1)Number of recalls issued,(2)total units recalledNone.HC-BP-250a.4 Total amount of product accepted for take-back,reuse,or di
292、sposalAmicus has implemented processes and procedures to properly dispose of unused product.Product does not get reintroduced again for reuse.HC-BP-250a.5 Number of enforcement actions taken in response to violations of current Good Manufacturing Practices(cGMP),by typeNone.Company OverviewEnvironme
293、ntal StewardshipPatientsEmployeesGovernanceAmicus Therapeutics2024 ESG Report45TopicAccounting MetricLocation Counterfeit DrugsHC-BP-260a.1 Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeitingAmicus has implemented p
294、rocesses and procedures to identify and address potential or known risks associated with counterfeit products.HC-BP-260a.2 Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit productsAmicus has implemented processes and procedure
295、s to identify and address potential or known risks associated with counterfeit products.HC-BP-260a.3 Number of actions that led to raids,seizure,arrests,and/or filing of criminal charges related to counterfeit productsNone.Ethical MarketingHC-BP-270a.1 Total amount of monetary losses as a result of
296、legal proceedings associated with false marketing claimsNone.Amicus Code of ConductHC-BP-270a.2 Description of code of ethics governing promotion of off-label use of productsAmicus does not promote products for unapproved uses.All promotional communications must meet the requirements of applicable l
297、ocal laws,regulations,industry codes,and other applicable guidance documents.Unsolicited requests for information about unapproved uses of Amicus products received while conducting promotional communications must be referred to Medical Information or Medical Affairs in accordance with applicable Ami
298、cus policies and procedures.Additionally,Amicus has clear standards and procedures in place for responding to unsolicited requests for information about unapproved Amicus products or unapproved uses of approved Amicus products.Amicus Code of ConductCompany OverviewEnvironmental StewardshipPatientsEm
299、ployeesGovernanceAmicus Therapeutics2024 ESG Report46TopicAccounting MetricLocation Employee Recruitment,Development,and RetentionHC-BP-330a.1 Discussion of talent recruitment and retention efforts for scientists and research and development staffEmployee Recruitment,Engagement and Retention(p.21-26
300、)HC-BP-330a.2(1)Voluntary and(2)involuntary turnover rate for:(a)executives/senior managers,(b)mid-level managers,(c)professionals,and(d)all othersHuman Capital(p.28)Supply Chain ManagementHC-BP-430a.1 Percentage of(1)entitys facilities and(2)Tier I suppliers facilities participating in the Rx-360 I
301、nternational Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredientsAmicus suppliers are screened for various legal and compliance risks in accordance with company policy.Company OverviewEnvironmental StewardshipPati
302、entsEmployeesGovernanceAmicus Therapeutics2024 ESG Report47TopicAccounting MetricLocation Business EthicsHC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption and briberyNone.Amicus Code of ConductHC-BP-510a.2 Description of code of ethics governing
303、 interactions with health care professionalsIn order to provide the best possible care to patients,Amicus provides the medical community with up-to-date information about its products at scientific congresses,during office visits,and at other appropriate venues.We also interact with healthcare profe
304、ssionals(HCP)as part of our clinical research programs.In all such interactions,we are committed to providing science-based,truthful,and non-misleading information about our products,and to paying no more than fair market value for needed and legitimate services such as research and consulting.Amicu
305、s has several global policies and Standard Operating Procedures(SOPs)that govern our relationships with HCPs.They include our Code of Conduct,Anti-Bribery,Interactions with HCPs,HCP Service Providers,and Advisory Boards.Employees must comply with these policies and SOPs and receive periodic training
306、 on these Policies and SOPs.Amicus Code of ConductActivity MetricsHC-BP-000.A Number of patients treated2,600(commercial,clinical,and expanded access).HC-BP-000.B Number of drugs(1)in portfolio and(2)in research and development(Phases 1-3)Amicus pipelineCompany OverviewEnvironmental StewardshipPatie
307、ntsEmployeesGovernanceAmicus Therapeutics2024 ESG Report48Our Commitment Demonstrating a commitment to ESG in order to drive resiliency and adaptability across all business units is our continuing promise to our people,our patients,and our communities.By understanding material ESG risks,assessments,
308、and controls,our organization is able to integrate these ESG factors into our decision-making process.Safe HarborThis report contains“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the inaugural ESG report and programs.The inclusion
309、of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved.Any or all of the forward-looking statements in this report may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and unce
310、rtainties.For example,statements regarding corporate ESG goals and the attainment of such goals,based on current information and actual results and performance may differ materially.In addition,all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for t
311、he year ended December 31,2023.You are cautioned not to place undue reliance on these forward-looking statements,which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement,and we undertake no obligation to revise or update this report to reflect events or circumstances after its publication date.Amicus Therapeutics,Inc.47 Hulfish StreetPrinceton,NJ
0731-84720580
sgpjbg002
工作日 9:30 - 18:00
报告分类
新质生产力
DeepSeek
低空经济
大模型
AI Agent
AI Infra
具身智能
自动驾驶
宠物
银发经济
人形机器人
企业出海
算力
微短剧
薪酬
白皮书
创新药
人工智能
AI产业
信息科技
互联网
消费经济
汽车交通
电商零售
传媒娱乐
医药健康
投资金融
能源环境
地产建筑
传统产业
英文报告
最新报告
中英对照
全文搜索
报告精选
PDF上传翻译
多格式文档互转
入驻&报告售卖
会员权益
机构报告
券商研报
财报库
专题合集
英文报告
数据图表
会议报告
其他资源
行业聚焦
芯片产业
热点概念
全球咨询智库
人工智能
500强
新质生产力
会议峰会
新能源汽车
企业年报
互联网
公司研究
行业综观
消费教育
科技通信
医药健康
人力资源
投资金融
汽车产业
物流地产
电子商务
传统产业
传媒营销
其它
2025低空经济/低空产业报告合集（共46套打包）
2025年美国对等关税/特朗普关税新政报告合集（共30套打包）
AI读财报
年报
一季报
半年报
三季报
IPO招股书
社会责任报告
A股
IPO申报
港股
美股&全球
新三板
AI、科技与通信
广告、传媒与营销
消费、零售与支付
HR、文化与旅游
金融、保险与投资
能源、环境与工业
医疗制药与大健康
物流、地产与建筑
其他行业
AI ▪ 科技 ▪ 通信
数字化
金融财经
智能制造
电商传媒
地产建筑
医疗医学
能源化工
其他行业
收藏
下载
2025-04-14
数据
AI查数
行业数据
政策法规
商业模式
产业链
竞争格局
市场规模
产业概述
其它
2025年
扫码登录
手机快捷登录
账号登录
